Verordnung die hypothecarische Sicherung der jüdischen Pupillen Gelder bereffend ... 5. Januar 1775

Von Gottes Gnaden, Wir Wilhelm Landgraf und Erbprinz zu Hessen

Die Abgaben und die Schuldenlast der Wormser jüd. Gemeinde : 1563 - 1854

ein Beitrag zur Geschichte der jüd. Gemeinde Worms mit zwei Briefen des A. Weckerling. Von S. Rothschild

Die Judenverfolgungen in Galizien und Rumänien : Rede, geh. von Jakob Klatzkin in d. v. Aktionskomitee d. ostjüd. Organisationen veranst. Massenkundgebung im Zürcher Volkshaus

Jakob Klatzkin

Festschrift zum siebzigsten Geburtstage Jakob Guttmanns

hrsg. vom Vorstande d. Gesellschaft zur Förderung d. Wissenschaft d. Judentums

Multidisciplinary consensus on assessment of unruptured intracranial aneurysms: proposal of an international research group.

BACKGROUND AND PURPOSE To address the increasing need to counsel patients about treatment indications for unruptured intracranial aneurysms (UIA), we endeavored to develop a consensus on assessment of UIAs among a group of specialists from diverse fields involved in research and treatment of UIAs. METHODS After composition of the research group, a Delphi consensus was initiated to identify and rate all features, which may be relevant to assess UIAs and their treatment by using ranking scales and analysis of inter-rater agreement (IRA) for each factor. IRA was categorized as very high, high, moderate, or low. RESULTS Ultimately, 39 specialists from 4 specialties agreed (high or very high IRAs) on the following key factors for or against UIA treatment decisions: (1) patient age, life expectancy, and comorbid diseases; (2) previous subarachnoid hemorrhage from a different aneurysm, family history for UIA or subarachnoid hemorrhage, nicotine use; (3) UIA size, location, and lobulation; (4) UIA growth or de novo formation on serial imaging; (5) clinical symptoms (cranial nerve deficit, mass effect, and thromboembolic events from UIAs); and (6) risk factors for UIA treatment (patient age and life expectancy, UIA size, and estimated risk of treatment). However, IRAs for features rated with low relevance were also generally low, which underlined the existing controversy about the natural history of UIAs. CONCLUSIONS Our results highlight that neurovascular specialists currently consider many features as important when evaluating UIAs but also highlight that the appreciation of natural history of UIAs remains uncertain, even within a group of highly informed individuals.

Cantate : Psalm 45 ; [Cantate aus Anlass der Feier der silbernen Hochzeit unseres ... Kaiserpaares ... Franz Joseph I. und ... Elisabeth Amalie Eugenia ; 24te April 1854 - 1879]

[in Musik gesetzt von] J[acob] Bachmann

Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland.

OBJECTIVE To assess safety up to 1 year of follow-up associated with prasugrel and clopidogrel use in a prospective cohort of patients with acute coronary syndromes (ACS). METHODS Between 2009 and 2012, 2286 patients invasively managed for ACS were enrolled in the multicentre Swiss ACS Bleeding Cohort, among whom 2148 patients received either prasugrel or clopidogrel according to current guidelines. Patients with ST-elevation myocardial infarction (STEMI) preferentially received prasugrel, while those with non-STEMI, a history of stroke or transient ischaemic attack, age ≥75 years, or weight <60 kg received clopidogrel or reduced dose of prasugrel to comply with the prasugrel label. RESULTS After adjustment using propensity scores, the primary end point of clinically relevant bleeding events (defined as the composite of Bleeding Academic Research Consortium, BARC, type 3, 4 or 5 bleeding) at 1 year, occurred at a similar rate in both patient groups (prasugrel/clopidogrel: 3.8%/5.5%). Stratified analyses in subgroups including patients with STEMI yielded a similar safety profile. After adjusting for baseline variables, no relevant differences in major adverse cardiovascular and cerebrovascular events were observed at 1 year (prasugrel/clopidogrel: cardiac death 2.6%/4.2%, myocardial infarction 2.7%/3.8%, revascularisation 5.9%/6.7%, stroke 1.0%/1.6%). Of note, this study was not designed to compare efficacy between prasugrel and clopidogrel. CONCLUSIONS In this large prospective ACS cohort, patients treated with prasugrel according to current guidelines (ie, in patients without cerebrovascular disease, old age or underweight) had a similar safety profile compared with patients treated with clopidogrel. CLINICAL TRIAL REGISTRATION NUMBER SPUM-ACS: NCT01000701; COMFORTABLE AMI: NCT00962416.

Die Amsterdamer Hagada : 18 Abb. aus d. Kupferstichdr. d. Passah-Hagada [ von Abraham Ber Jakob. Hrsg. Moses Wesel]

Mit Stempel der Bibliothek der Jüdischen Gemeinde Berlin

Der Spinozismus im Jüdenthumb, oder, Die von dem heütigen Jüdenthumb und dessen Geheimen Kabbala vergötterte Welt : an Mose Germano sonsten Johan Peter Speeth ...

befunden und widerleget von Johann Georg Wachter